A profitability focus with operating profit as the target metric
First written in FY2017. 17 of 31 entries say "Advanced", first in FY2018-Q1. Latest entry: 2026-08-10.
The whole theme swung hardest in 2019: 14 of 100 companies on the "Worse" side.
29 other companies' latest entry also says "Advanced".
- FY2025RaisedAnnual report
「The actual result for the current consolidated fiscal year was ¥1,606.662 million against the target of ¥1,600 million, representing an achievement rate of 100.4%. For the next consolidated fiscal year, the target is ¥2,050 million, up 27.6% from the current consolidated fiscal year’s actual result. The Company will seek to grow performance by strengthening sales to medical and nursing-care providers through closer regional collaboration, while also advancing initiatives in cooperation with national and local governments.」
The operating profit target of ¥1,600 million for the current consolidated fiscal year was achieved at a rate of 100.4%, and the target for the next consolidated fiscal year has been raised to ¥2,050 million. - FY2025-H1AdvancedAnnual report
「As a result, performance for the current interim consolidated accounting period comprised revenue of ¥2,661.188 million, up ¥214.821 million, or 8.8%, year on year, and operating profit of ¥764.704 million, up ¥95.712 million, or 14.3%, year on year.」
Regarding its policy of prioritizing profitability, the Company reports interim operating profit of ¥764.704 million, an increase of 14.3% year on year. - FY2024RaisedAnnual report
「The actual result for the current consolidated fiscal year was ¥1,439.155 million against the target of ¥1,500 million, representing an achievement rate of 95.9%. This was attributable to the factors described in “(2) Analysis and review of operating results and other conditions from management’s perspective, ① Recognition, analysis and review of financial position and operating results.” For the next consolidated fiscal year, the target is ¥1,700 million, up 13.3% from the current consolidated fiscal year’s actual result. The Company will seek to grow performance by strengthening sales to medical and nursing-care providers through closer regional collaboration, while also advancing initiatives in cooperation with national and local governments.」
The operating profit target of ¥1,500 million for the current consolidated fiscal year was not achieved, with an achievement rate of 95.9%, while the target for the next consolidated fiscal year has been raised to ¥1,700 million. - FY2024-Q2AdvancedAnnual report
「As a result, for the second quarter consolidated cumulative period, net sales were ¥2,446.366 million, up ¥709.396 million or 40.8% year on year; operating profit was ¥668.991 million, up ¥109.691 million or 19.6%; ordinary profit was ¥675.282 million, up ¥110.108 million or 19.5%; and quarterly net income attributable to owners of the parent was ¥458.071 million, up ¥52.343 million or 12.9%.」
Regarding the profitability-focused policy, second-quarter cumulative operating profit was ¥668.991 million, up 19.6% year on year. - FY2024-Q1AdvancedAnnual report
「As a result, for the first quarter consolidated cumulative period, net sales were ¥1,192.515 million, up ¥394.575 million or 49.4% year on year; operating profit was ¥307.773 million, up ¥73.318 million or 31.3%; ordinary profit was ¥308.065 million, up ¥70.283 million or 29.6%; and quarterly net income attributable to owners of the parent was ¥207.989 million, up ¥42.416 million or 25.6%.」
Regarding the profitability-focused policy, first-quarter operating profit was ¥307.773 million, up 31.3% year on year. - FY2023RaisedAnnual report
「Actual operating profit for the current consolidated fiscal year was ¥1,096.080 million against a target of ¥1,150.000 million, representing an achievement rate of 95.3%. This was due to the factors described in “(2) Analysis and Review of the Status of Business Results, etc. from Management’s Perspective, ① Recognition, Analysis and Review of Financial Position and Business Results.” The target for the following consolidated fiscal year is ¥1,400.000 million, up 27.7% from the current consolidated fiscal year's actual result, and the company will seek to improve performance by strengthening sales efforts to medical and nursing-care providers through enhanced regional collaboration and by advancing businesses jointly with national and local governments.」
The current consolidated fiscal year's operating profit target of ¥1,150.000 million was not achieved, with an achievement rate of 95.3%, while the target for the following consolidated fiscal year was raised to ¥1,400.000 million. - FY2023-Q3AdvancedAnnual report
「As a result, for the third quarter consolidated cumulative period, net sales were ¥2,660.824 million, up ¥1,032.921 million or 63.5% year on year; operating profit was ¥805.932 million, up ¥180.955 million or 29.0%; ordinary profit was ¥814.088 million, up ¥189.278 million or 30.3%; and quarterly net income attributable to owners of the parent was ¥553.607 million, up ¥133.365 million or 31.7%.」
Regarding the profitability-focused policy, the company reported third-quarter cumulative operating profit of ¥805.932 million, up 29.0% year on year. - FY2023-Q2AdvancedAnnual report
「As a result, for the second quarter consolidated cumulative period, net sales were ¥1,736.970 million, up ¥668.639 million or 62.6% year on year; operating profit was ¥559.300 million, up ¥124.227 million or 28.6%; ordinary profit was ¥565.174 million, up ¥129.951 million or 29.9%; and quarterly net income attributable to owners of the parent was ¥405.727 million, up ¥106.376 million or 35.5%.」
Regarding the profitability-focused policy, operating profit for the second quarter consolidated cumulative period was ¥559.300 million, up 28.6% year on year. - FY2023-Q1AdvancedAnnual report
「As a result, for the first quarter consolidated cumulative period, net sales were ¥797.940 million, up ¥278.696 million or 53.7% year on year; operating profit was ¥234.455 million, up ¥31.201 million or 15.4%; ordinary profit was ¥237.782 million, up ¥34.545 million or 17.0%; and quarterly net income attributable to owners of the parent was ¥165.572 million, up ¥25.783 million or 18.4%.」
Under the policy of prioritizing operating profit, first-quarter operating profit was ¥234.455 million, up 15.4% year on year. - FY2022-Q3Year-on-year decline in operating incomeAnnual report
「As a result, for the third quarter consolidated cumulative period, net sales were ¥1,627.903 million, up ¥72.554 million or 4.7% year on year; operating profit was ¥624.977 million, down ¥12.698 million or 2.0%; ordinary profit was ¥624.809 million, down ¥17.343 million or 2.7%; and quarterly net income attributable to owners of the parent was ¥420.241 million, down ¥25.744 million or 5.8%.」
While net sales increased 4.7% year on year, operating profit was ¥624.977 million, down 2.0% year on year. - FY2022-Q2AdvancedAnnual report
「As a result, for the second quarter consolidated cumulative period, net sales were ¥1,068.330 million, up ¥25.072 million or 2.4% year on year, and operating profit was ¥435.073 million, up ¥16.373 million or 3.9%.」
Regarding the profitability-focused policy, operating profit was ¥435.073 million for the second quarter cumulative period, up 3.9% year on year. - FY2022-Q1Operating profit slightly lower year on yearAnnual report
「As a result, for the first quarter consolidated cumulative period, net sales were ¥519.244 million, down ¥14.229 million or 2.7% year on year; operating profit was ¥203.253 million, down ¥0.697 million or 0.3%; ordinary profit was ¥203.237 million, down ¥3.564 million or 1.7%; and quarterly net income attributable to owners of the parent was ¥139.788 million, down ¥3.857 million or 2.7%.」
Under the policy of prioritizing operating profit, first-quarter operating profit was ¥203.253 million, down 0.3% year on year. - FY2021RaisedAnnual report
「Actual operating profit for the current consolidated fiscal year was ¥841.805 million against a target of ¥730.000 million, representing an achievement rate of 115.3%. The target for the following consolidated fiscal year is ¥930.000 million, up 10.5% from the current consolidated fiscal year's actual result, and the company will seek to improve performance by strengthening sales efforts to medical and nursing-care providers through enhanced regional collaboration and by advancing businesses jointly with national and local governments.」
The company exceeded its operating profit target of ¥730.000 million, achieving an achievement rate of 115.3%, and raised the target for the following consolidated fiscal year to ¥930.000 million. - FY2021-Q3AdvancedAnnual report
「As a result, for the third quarter consolidated cumulative period, net sales were ¥1,555.348 million, up ¥189.748 million or 13.9% year on year; operating profit was ¥637.676 million, up ¥171.848 million or 36.9%; ordinary profit was ¥642.153 million, up ¥156.795 million or 32.3%; and quarterly net income attributable to owners of the parent was ¥445.985 million, up ¥121.123 million or 37.3%.」
Regarding the profitability-focused policy, the company reported an improvement in third-quarter operating profit to ¥637.676 million, up 36.9% year on year. - FY2021-Q2AdvancedAnnual report
「As a result, for the second quarter consolidated cumulative period, net sales were ¥1,043.257 million, up ¥134.458 million or 14.8% year on year; operating profit was ¥418.699 million, up ¥121.364 million or 40.8%; ordinary profit was ¥423.107 million, up ¥106.068 million or 33.5%; and quarterly net income attributable to owners of the parent was ¥295.155 million, up ¥82.178 million or 38.6%.」
Regarding the profitability-focused policy, operating profit for the second quarter consolidated cumulative period was ¥418.699 million, up 40.8% year on year. - FY2021-Q1AdvancedAnnual report
「As a result, for the first quarter consolidated cumulative period, net sales were ¥533.473 million, up ¥113.848 million or 27.1% year on year; operating profit was ¥203.951 million, up ¥103.718 million or 103.5%; ordinary profit was ¥206.801 million, up ¥105.273 million or 103.7%; and quarterly net income attributable to owners of the parent was ¥143.646 million, up ¥74.211 million or 106.9%.」
Regarding the profitability-focused policy targeting operating profit, the company reported first-quarter operating profit of ¥203.951 million, up 103.5% year on year. - FY2020-Q3RestatedAnnual report
「As a result, for the third quarter consolidated cumulative period, net sales were ¥1,365.599 million, operating profit was ¥465.828 million, ordinary profit was ¥485.357 million, and quarterly net income attributable to owners of the parent was ¥324.862 million.」
Regarding the profitability-focused policy, the company reported operating profit of ¥465.828 million for the third quarter consolidated cumulative period, but did not provide a year-on-year comparison or the achievement status against the full-year target. - FY2020-Q2RestatedAnnual report
「As a result, for the second quarter consolidated cumulative period, net sales were ¥908.798 million, operating profit was ¥297.334 million, ordinary profit was ¥317.039 million, and quarterly net income attributable to owners of the parent was ¥212.976 million.」
Regarding the profitability-focused policy, the company reported operating profit of ¥297.334 million for the second quarter consolidated cumulative period, but did not provide a year-on-year comparison or the achievement status against the full-year target. - FY2020-Q1AdvancedAnnual report
「As a result, for the first quarter consolidated cumulative period, net sales were ¥419.625 million, operating profit was ¥100.232 million, ordinary profit was ¥101.528 million, and quarterly net income attributable to owners of the parent was ¥69.435 million.」
Regarding the profitability-focused policy, the company reported operating profit of ¥100.232 million for the first quarter consolidated cumulative period. No comparative analysis against the same quarter of the previous year was conducted. - FY2019RaisedAnnual report
「Actual operating profit for the current fiscal year was ¥544.577 million against a target of ¥450.000 million, representing an achievement rate of 121.0%. This was due to the factors described in “(2) Business Results, etc. ① Business Results.” The target for the following fiscal year is ¥610.000 million, up 12.0% from the current fiscal year's actual result, and the company will seek to improve performance by strengthening sales efforts to medical and nursing-care providers through enhanced regional collaboration and by advancing businesses jointly with national and local governments.」
The company achieved operating profit of ¥544.577 million against a target of ¥450.000 million, for an achievement rate of 121.0%, and raised the target for the following fiscal year to ¥610.000 million. - FY2019-Q3AdvancedAnnual report
「As a result, for the third quarter cumulative period, net sales were ¥1,245.543 million, up ¥115.291 million or 10.2% year on year; operating profit was ¥403.317 million, up ¥85.048 million or 26.7%; ordinary profit was ¥403.246 million, up ¥89.063 million or 28.3%; and quarterly net income was ¥263.655 million, up ¥58.871 million or 28.7%.」
The company reported an improvement in the third quarter cumulative period, with operating profit of ¥403.317 million, up 26.7% year on year. - FY2019-Q2AdvancedAnnual report
「Operating profit for the second quarter cumulative period increased by ¥38.066 million year on year to ¥264.965 million.」
Regarding the profitability-focused policy targeting operating profit, the company reported operating profit of ¥264.965 million, up 16.8% year on year. - FY2019-Q1Year-on-year decline in operating incomeAnnual report
「Operating profit for the first quarter cumulative period decreased by ¥9.599 million year on year to ¥92.642 million. Gross profit increased by ¥28.185 million to ¥337.774 million, while selling, general and administrative expenses increased by ¥37.784 million to ¥245.132 million. The main factor behind the increase in selling, general and administrative expenses was the recognition as a one-time expense of ¥27.900 million in joint research costs with Asahikawa Medical University, a national university corporation, for the one-year period from October 2018 to September 2019, among other factors.」
Although net sales increased, operating profit decreased 9.4% year on year due in part to the one-time recognition of ¥27.900 million in joint research costs with Asahikawa Medical University. The company states that there were no material changes to its management policies, management strategies or other related matters. - FY2018AchievedAnnual report
「Actual operating profit for the current fiscal year was ¥399.021 million against a target of ¥360.000 million, representing an achievement rate of 110.8%. This was due to the factors described in “(2) Business Results, etc. ① Business Results.” The target for the following fiscal year is ¥450.000 million, up 12.8% from the current fiscal year, and the company will seek to improve performance by strengthening sales efforts to medical and nursing-care providers through enhanced regional collaboration and by advancing businesses jointly with national and local governments.」
The company achieved operating profit of ¥399.021 million against the current fiscal year's target of ¥360.000 million, for an achievement rate of 110.8%. It set a target of ¥450.000 million for the following fiscal year, citing stronger regional collaboration and business initiatives with national and local governments as the means. - FY2018-Q3AdvancedAnnual report
「As a result, for the third quarter cumulative period, net sales were ¥1,130.251 million, up ¥188.583 million or 20.0% year on year; operating profit was ¥318.269 million, up ¥77.242 million or 32.0%; ordinary profit was ¥314.182 million, up ¥73.423 million or 30.5%; and quarterly net income was ¥204.784 million, up ¥52.687 million or 34.6%.」
Regarding the profitability-focused policy, the company reported operating profit of ¥318.269 million for the third quarter cumulative period, up 32.0% year on year. - FY2018-Q2AdvancedAnnual report
「As a result, for the second quarter cumulative period, net sales were ¥762.493 million, up ¥132.359 million or 21.0% year on year; operating profit was ¥226.898 million, up ¥56.259 million or 33.0%; ordinary profit was ¥226.839 million, up ¥56.410 million or 33.1%; and quarterly net income was ¥146.925 million, up ¥39.961 million or 37.4%.」
Regarding the profitability-focused policy, the company reported operating profit of ¥226.898 million for the second quarter cumulative period, up 33.0% year on year. - FY2018-Q1AdvancedAnnual report
「As a result, for the first quarter cumulative period, net sales were ¥348.230 million, up ¥58.053 million or 20.0% year on year; operating profit was ¥102.241 million, up ¥42.501 million or 71.1%; ordinary profit was ¥102.207 million, up ¥42.636 million or 71.6%; and quarterly net income was ¥67.586 million, up ¥29.714 million or 78.5%.」
Regarding the profitability-focused policy targeting operating profit, the company reported a measurable improvement, with operating profit of ¥102.241 million, up 71.1% year on year. - FY2017First statedAnnual report
「With a focus on profitability, the company uses operating profit as its target metric, continually works to improve earnings and manages the business with an emphasis on cost reduction.」
The company has explicitly identified, for the first time, a profitability-focused management metric targeting operating profit, with earnings improvement and cost reduction as its means of achieving it.